Delivery Order SPE2DB22D1103-SPE2DB25FH0K7
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,715.83 on July 29, 2025, for the supply of Fluticasone Propionate HFA 44 microgram inhalers (10.6 grams). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, with a contract value of $24,494.88 and an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,591.71 to AmerisourceBergen Drug Corp for the supply of Fluticasone Propionate HFA 110 mcg inhalers (12-gram units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a single transaction under a larger contract vehicle supporting federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Fluticasone Propionate HFA 44 mcg 10.6gm inhalers, valued at $1,257.22. This is a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $42,827.06 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 110 microgram inhalers (12-gram units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside award issued under competitive procedures. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, with a ceiling value of $1,504.06. This firm fixed-price delivery order, which was competitively awarded without a set-aside designation, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The contract specifies Conshohocken, Pennsylvania as the place of...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers. This is a firm fixed-price, non-set-aside contract with a ceiling value of $1,051.91 and an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 44 mcg inhalers (10.6 gm) valued at $2,799.78 on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitive award under the company's existing contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, valued at $5,930.40. This is a firm fixed price contract with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Fluticasone Propionate HFA 220 MCG 12GM inhalers, valued at $5,454.12. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and requires delivery by August 5, 2025, with performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, designated...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH0K7Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,817.34 on August 19, 2025, for the supply of Fluticasone Propionate HFA 110 mcg inhalers (12 grams). This contract represents a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order falls under AmerisourceBergen's comprehensive $999.9 billion Pharmaceutical Prime Vendor Global Program IDC with DLA Troop Support Medical (contract SPE2DX), which extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies pharmaceutical products and medical supplies to military healthcare systems, the Defense Health Agency, and other government healthcare entities. This particular order for the respiratory medication supports the company's role in providing essential pharmaceutical commodities across multiple therapeutic domains to sustain federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/19/25 |